Fierce Pharma

JULY 18, 2024

Pfizer’s blockbuster drug tafamidis for the treatment of the rare heart disease transthyretin amyloid cardiomyopathy (ATTR-CM) needs at least a 96% discount off its list price to be considered cost | Pfizer’s blockbuster tafamidis for the treatment of the rare heart disease ATTR-CM needs at least a 96% discount off its list price to be considered cost-effective under common benchmarks, a draft report by ICER has found.

316

316

MedCity News

JULY 18, 2024

The Federal Trade Commission recently released an interim report that details how the practices of pharmacy benefit managers negatively impact patients and pharmacies. Some experts hope for legislative action based on the report. The post The FTC Released a Scathing Interim Report on PBMs. What’s Next? appeared first on MedCity News.

Management 130

Management Patients 130

Fierce Pharma

JULY 18, 2024

As biopharma companies and the U.S. | As biopharma companies and the U.S. government near the deadline of their drug price talks under the Inflation Reduction Act, Novartis CEO said the cost cuts “might be manageable” in the short term for the firm’s first few products to be included.

Management 253

Management Biopharma Government 253

pharmaphorum

JULY 18, 2024

The House Committee on Oversight and Accountability will quiz leaders of pharmacy benefit managers (PBMs) at a hearing next week, amid scrutiny of the sector's role in rising healthcare costs in the US.The hearing – scheduled for 23rd July – is part of an ongoing investigation by the committee into PBMs' alleged anticompetitive practices launched last year and spearheaded by chairman James Comer (R-Ky).

Healthcare 110

Healthcare Healthcare Management 110

Advertisement

What if you could help your sellers stop wasting 72% of their day on non-selling activities and focus on bringing in revenue? Incorporating AI in your enablement workflows can help you cut down on busy work, get projects done faster, and let your team (and you!) focus on making a bigger impact. We put together this guide to show you how to use AI to cut time and costs for projects, including collateral creation, development of training videos, and automating tedious processes.

Sales Management

Fierce Pharma

JULY 18, 2024

After storming the market with its longer-acting macular degeneration shot Vabysmo, Roche is laying the groundwork to expand the reach of its other eye disease innovation—refillable implant Susvimo | After storming the market with its longer-acting macular degeneration shot Vabysmo, Roche is laying the groundwork to expand the reach of its other eye disease innovation—refillable implant Susvimo.

Marketing 237

Marketing 237

MedCity News

JULY 18, 2024

SMS is reevaluating its Star Ratings. Not only do health plans stand to benefit from the new calculations — all healthcare companies and millions of patients will reap the rewards. The post What the Medicare Quality Rating Change Means for Healthcare Companies — and Patient Health appeared first on MedCity News.

Healthcare 105

Healthcare Healthcare Patients Physicians 105

MedCity News

JULY 18, 2024

Expanded FDA approval of Phathom Pharmaceuticals drug Voquezna now includes patients with non-erosive gastroesophageal reflux disease (GERD). Phathom licensed its flagship product from Takeda Pharmaceutical. The post Heartburn Drug from Phathom Pharma Expands Its Approval to Cover More GERD Patients appeared first on MedCity News.

Pharma 103

Pharma Patients FDA Pharmaceutical 103

Fierce Pharma

JULY 18, 2024

The addition of Bristol Myers Squibb’s Opdivo to a low dose of Aveo Oncology’s Fotivda failed to extend the time before tumor progression or death in kidney cancer patients who had tried an im | The addition of Bristol Myers Squibb’s Opdivo to a low dose of Aveo Oncology’s Fotivda failed to extend the time before tumor progression or death compared with Fotivda alone in kidney cancer patients who had tried an immune checkpoint inhibitor.

Patients 229

Patients 229

MedCity News

JULY 18, 2024

In addition to increasing medication access for underserved populations, an in-house specialty pharmacy improves patient care and provides opportunities for efficiency and enhancement across hospital operations. The post Specialty Pharmacy: A Sound Strategy to Weather Hospital Financial Storms, Enhance Patient Care appeared first on MedCity News.

Patients 103

Patients Medical 103

Fierce Pharma

JULY 18, 2024

Even as argenx begins to chart a course toward a future beyond Vyvgart, the company’s flagship FcRn inhibitor still has plenty of tricks in store for the remainder of the decade. | Even as argenx begins to chart a course toward a future beyond Vyvgart, the company’s flagship FcRn inhibitor still has plenty of tricks in store for the remainder of the decade.

Patients 233

Patients 233

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

Patients

pharmaphorum

JULY 18, 2024

J&J has three of its top-selling drugs in Medicare pricing negotiations but does not expect a major hit to its finances next year

112

112

Fierce Pharma

JULY 18, 2024

After its buyout last summer by Novo Holdings and Gurnet Point, Paratek Pharmaceuticals reaffirmed the benefits of its Biomedical Advanced Research and Development Authority (BARDA)-backed Nuzyra w | After its buyout last summer by Novo Holdings and Gurnet Point, Paratek Pharmaceuticals reaffirmed the benefits of its BARDA-backed Nuzyra with a positive post-marketing study.

Marketing 224

Marketing Pharmaceutical 224

MedCity News

JULY 18, 2024

The Salt Lake City health system will pilot NeuroFlow’s behavioral health tech platform and services in five primary care locations in Colorado. The first step is to integrate technology into its Epic EHR but the broader goal is to create the mechanism by which behavioral healthcare can be standardized and measured. The post What Intermountain Health Hopes to Achieve with its New Behavioral Health Partnership appeared first on MedCity News.

Healthcare 101

Healthcare Healthcare 101

Pharmaceutical Technology

JULY 18, 2024

The new hub will act as a central point of connection and engagement for the rare disease community for FDA-related concerns.

FDA 111

FDA 111

Advertisement

Every marketer knows how important it is to prove their efforts drive sales opportunities, but that’s easier said than done. When problems like sales and marketing misalignment, lack of data, and wasted efforts persist, marketers can’t measure, prove, or increase their impact on revenue at a time when demonstrating marketing value is critical. Using analyst and expert data, this guide to marketing impact and content attribution explains: How B2B buyers use content The most common types of conten

Sales

pharmaphorum

JULY 18, 2024

Boehringer Ingelheim has joined forces with digital health firm Brainomix on a project to improve the care of people with fibrosing lung diseases

102

102

MedCity News

JULY 18, 2024

The new CMS guidelines represent a transformative moment for Medicare Advantage — here are three ways to be good stewards of taxpayer dollars and create a healthier future for seniors The post Supplemental Benefits are Worth Fighting for to Support Senior Health appeared first on MedCity News.

95

95

pharmaphorum

JULY 18, 2024

Ursula von der Leyen highlights biotech and AI as key sectors in speech as she is re-elected as President of the European Commission

104

104

Pharmaceutical Technology

JULY 18, 2024

Johnson & Johnson has reported a 12.8% decrease in net earnings for Q2 2024, with figures falling to $4.6bn from $5.3bn in Q2 2023.

97

97

Advertisement

PharmaVoice

JULY 18, 2024

With a long elusive HIV cure ever on the horizon, Gilead’s latest long-acting PrEP study shows that every step counts.

98

98

PharmaTimes

JULY 18, 2024

Genentech’s Pulmozyme could also treat other respiratory infections and conditions

103

103

pharmaphorum

JULY 18, 2024

Gilead Sciences' chief medical officer Merdad Parsey has said he will leave the company in early 2025

Medical 94

Medical 94

PharmaTimes

JULY 18, 2024

The most commonly diagnosed cancer in men in the UK leads to over 12,000 annual deaths

Leads 100

Leads 100

Advertisement

Quotas need to be hit. Revenue goals need to be met. This reality makes shortening sales onboarding time a top priority. Organizations with a standard onboarding process boost employee retention by 58% and increase productivity by 50%. Unfortunately, many companies struggle with inefficient processes that lead to high turnover and missed revenue opportunities.

Sales

European Pharmaceutical Review

JULY 18, 2024

What are antibody-drug conjugates and why do they hold potential over other treatment modalities? Antibody drug conjugates (ADCs) are an emerging technology adding significant value to the oncology treatment landscape. They are also increasingly the focus of R&D across the world and remain a modality that is regularly the focus of deals across the industry. 1 As they can be highly targeted in their action, they could become the treatment of choice for clinicians and patients due to the reduc

Food and Drug Administration 59

Food and Drug Administration Engineering Pharmacology Side effects 59

pharmaphorum

JULY 18, 2024

Discover valuable tips for ensuring on-time tech transfers within budget in this podcast featuring industry experts Frantz Maignan, Grant Brock from Lannett CDMO.

59

59

Pharmaceutical Technology

JULY 18, 2024

hVIVO specialises in human challenge trials for influenza and RSV therapeutic candidates.

81

81

Nixon Gwilt Law

JULY 18, 2024

Last week, the Centers for Medicare & Medicaid Services (CMS) released the 2025 Medicare Physician Fee Schedule Proposed Rule (the Proposed Rule). In alignment with the U.S. Department of Health and Human Services (HHS) Initiative to Strengthen Primary Health Care , CMS introduced new reimbursement opportunities for primary care practices providing what they refer to as “enhanced care management” for their patients.

Management 52

Management Physicians Patients Medicine 52

Advertisement

Distribution

Copyright Clearance Center

JULY 18, 2024

CCC introduced artificial intelligence (AI) re-use rights within its Annual Copyright Licenses (ACL), an enterprise-wide content licensing solution offering rights from millions of works to businesses that subscribe.

52

52

Nixon Gwilt Law

JULY 18, 2024

The New Advanced Primary Care Management HCPCS Codes Under the Proposed Rule, physicians and non-physician practitioners – for example, nurse practitioners (NPs) and physician assistants (PAs) – can order and bill for APCM services. Notably, CMS specifically states that the practitioner who bills for APCM services intends to be responsible for the patient’s primary care and is the continuing focal point for all needed health care services.

Management 52

Management Physicians Medicine Patients 52

Pharmaceutical Commerce

JULY 18, 2024

In an interview with Pharma Commerce editor Nicholas Saraceno, Matthew Walsh, ixlayer’s manager of biopharma, discusses findings of a new physician survey that the company conducted.

Biopharma 52

Biopharma Physicians Pharma Management 52

European Pharmaceutical Review

JULY 18, 2024

A report produced by the Centre for Process Innovation (CPI), alongside CDMO FUJIFILM Diosynth Biotechnologies, has acknowledged “significant” gaps in the UK skills and workforce for RNA therapeutics. The future workforce could require “at least 150 future capabilities to meet RNA vaccine and treatment demand”, according to the report. To support the manufacturing of RNA medicines, these capabilities include development of new equipment and reagents to increase efficiencies, the report

Manufacturing 52

Manufacturing Medicine Education Training 52

Advertisement

Are your sellers unsure about using AI in their day-to-day workflows? Or are they eager to try but uncertain where to start? They might be asking: Which tasks are best suited for AI? How will using AI affect my relationship with my customers? With so many tools available, which ones are the most useful to me? To help answer these and other common questions about using AI during the sales cycle, we surveyed B2B sellers who were early adopters to get their insight and advice about how to use gen A

Sales